San Francisco, Oct. 17, 2017 – Recardio presented today its clinical regenerative therapy program for cardiovascular diseases at the international BIO Investor Forum 2017 in San Francisco.

After completion of the Phase 1 study with dutogliptin and confirmation of the drug’s safety Recardio is now initiating a global, randomized, double-blind, placebo-controlled, safety and efficacy Phase 2 Study of dutogliptin in combination with filgrastim in early recovery post-myocardial infarction.

Roman Schenk, Executive Chairman of Recardio, has presented the clinical development program for this indication and the therapeutic platform for the regenerative medication for patients with a range of cardiovascular diseases.

The investor forum explores investment trends and opportunities in life sciences, with a focus on venture-stage growth and emerging public companies as well as those poised to join the growth “watch list” in 2018. Because the mission is to support industry-wide success, the bio forum strives to present a broad and unbiased view of investment opportunities and companies. It is an important event for the biotechnology field and provides a great opportunity to network and partner up with other companies and delegates from this area. Recardio was invited to present itself after a selection process in the discovery companies track.

More information about the clinical program is available by visiting the following link.

 

About Recardio

Recardio Inc. is a clinical-stage life science company focusing on regenerative therapies for cardiovascular diseases. The company’s lead drug candidate, dutogliptin, is a DPP-IV inhibitor that has demonstrated significant effects in activating SDF-1, a protein that is critical for cardiac regeneration. The company is pursuing a Phase 2 clinical program, seeking to fully develop the therapeutic platform as a regenerative medication for patients with various cardiovascular diseases including acute myocardial infarction and chronic heart failure, with the potential of improving heart function, quality of life and survival.  For more information, visit: http://www.recardio.eu/

San Francisco, October 12th, 2017 – Recardio Inc. successfully completes Phase 1 study for Dutogliptin.

Recardio Inc. today announced that it has successfully completed a Phase 1 single and multiple ascending dose clinical study with dutogliptin. This study enrolled 45 healthy humans at a single site in Vienna, Austria with AGES approval under a US IND.

“The Phase 1 single and multiple ascending dose study with dutogliptin confirmed the drug’s safety and established an understanding of the subcutaneous pharmacokinetic and pharmacodynamic properties, enabling us to select the dose for Phase 2.”  said Darrell Nix, Chief Scientific Officer of Recardio.

 

Recardio is now initiating a global, randomized, double-blind, placebo-controlled, safety and efficacy Phase 2 Study of dutogliptin in combination with filgrastim in early recovery post-myocardial infarction.

“Opening an IND and completion of the Phase 1 study represent important milestones in our efforts to bring this important treatment to patients with acute myocardial infarction.” said Roman Schenk, Executive Chairman of Recardio. “This Phase 1 study is also the foundation for our development of a therapeutic platform with dutogliptin as a regenerative medication for patients with a range of cardiovascular diseases.”

More information about the clinical program is available by visiting the following link.

 

About Recardio

Recardio Inc. is a clinical-stage life science company focusing on regenerative therapies for cardiovascular diseases. The company’s lead drug candidate, dutogliptin, is a DPP-IV inhibitor that has demonstrated significant effects in activating SDF-1, a protein that is critical for cardiac regeneration. The company is pursuing a Phase 2 clinical program, seeking to fully develop the therapeutic platform as a regenerative medication for patients with various cardiovascular diseases including acute myocardial infarction and chronic heart failure, with the potential of improving heart function, quality of life and survival.  For more information, visit: http://www.recardio.eu/

San Francisco, Aug. 28th, 2017 – RECARDIO, announced that the European Patent Office (EPA) has issued the notice of allowance for its innovative use patent for the treatment of ischemic diseases.

This patent is the result of research conducted since 2006, part of RECARDIO’s broad patent claims and covers the combination therapy of G-CSF and any DPP-IV compound in cardiovascular diseases. The company’s intellectual property estate enables now efficient and protected development of its innovative cardiac therapies in all major markets. In addition RECARDIO has exklusive protection for its lead drug Dutogliptin in all these markets.

Dr. Roman Schenk, RECARDIO’s  Executive Chairman and founder said: “ The issuance of this umbrella patent is an additional major step towards our strategy to protect and establish our regenerative therapies and to safeguard its marketing in key global markets”.

 

About Recardio

Recardio Inc. is a clinical-stage life science company focusing on regenerative therapies for cardiovascular diseases. The company’s lead drug candidate, Dutogliptin, is a DPP-IV inhibitor that has demonstrated significant effects in activating SDF-1, a protein that is critical for cardiac regeneration. The company is initiating a Phase 2 clinical program, seeking to fully develop the therapeutic platform as a regenerative medication for patients with various cardiovascular diseases including acute myocardial infarction and chronic heart failure, with the potential of improving heart function, quality of life and survival. For more information, visit: http://www.recardio.eu/

 

San Francisco, Jul. 25, 2017 – Recardio is participating in the European Society of Cardiology Congress in Barcelona.

Read More

San Francisco, June 21st, 2017 – Recardio Inc. today announced that it has appointed its newly formed Scientific Advisory Board, reflecting the company’s entering the clinical phase 2 development in 2017.

Read More